Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial (vol 402, pg 798, 2023)

被引:0
作者
Becker, J. C.
Ugurel, S.
Leiter, U.
机构
关键词
D O I
10.1016/S0140-6736(23)02294-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1422 / 1422
页数:1
相关论文
共 1 条
[1]   Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial [J].
Becker, Joergen C. ;
Ugurel, Selma ;
Leiter, Ulrike ;
Meier, Friedegund ;
Gutzmer, Ralf ;
Haferkamp, Sebastian ;
Zimmer, Lisa ;
Livingstone, Elisabeth ;
Eigentler, Thomas K. ;
Hauschild, Axel ;
Kiecker, Felix ;
Hassel, Jessica C. ;
Mohr, Peter ;
Fluck, Michael ;
Thomas, Ioannis ;
Garzarolli, Marlene ;
Grimmelmann, Imke ;
Drexler, Konstantin ;
Spillner, Alexandra N. ;
Eckhardt, Sebastian ;
Schadendorf, Dirk .
LANCET, 2023, 402 (10404) :798-808